B Braun Medical US and CeGaT GmbH have announced the establishment of a U.S. based company to enter the US diagnostics market.

Globally, Diagnostic Panels, a CeGaT innovation, were first made available in 2010. The worldwide demand for molecular diagnostics is growing explosively, therefore to supply the US market with the highest quality Diagnostic Panels and molecular diagnostic services, B Braun US and CeGaT have combined forces and established a US company based in B Braun Medical’s Bethlehem headquarters, Pennsylvania. The name of the new company is B Braun CeGaT, LLC.

Diagnostic Panels enable CeGaT to sequence all of the genes associated with a given disease simultaneously by means of Next-Generation-Sequencing (NGS). This approach is much faster and considerably less expensive than the classical Sanger-based gene-by-gene sequencing which was state-of-the-art until 2010. In addition, the probability of finding a pathogenic gene variation is significantly enhanced by the use of Diagnostic Panels. Diagnostic Panels evaluate all genes associated with the patient’s phenotype. This results in a highly accurate and reliable medical report issued based on the findings of the sequencing run, the medical history of the patient and their relevant family information. This report enables the referring clinician to select the best possible therapy for each individual case.

“Pennsylvania is a fantastic centralized location for a molecular diagnostics business,” says Dr. Dirk Biskup, Founder and CEO of CeGaT.

“After many years of experience in the design, sequencing, and analysis of Diagnostic Panels in Germany, we can offer a real value and treatment decision support to the clinicians in the US.”

Paul O’Connell, President of B Braun CeGaT, LLC, adds, “It is our goal to serve the US health care market with a dedicated team and the highest possible standard in molecular diagnostics.”